Updates from IKCS 2023 and Surrounding Meetings in Advanced RCC - Episode 6
Future Outlooks in the Treatment of Advanced RCC
Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.
This is a video synopsis/summary of a Post Conference Perspectives featuring Brian Rini, MD, and Hans Hammers, MD, PhD.
As they conclude, Rini and Hammers briefly discuss additional kidney cancer agents and studies presented at the 2023 International Kidney Cancer Symposium (IKCS). These include nivolumab with relatlimab and a phase 3 trial in metastatic papillary renal cell carcinoma.
Regarding future development of the novel tyrosine kinase inhibitor (TKI) zanzalintinib, Hammers proposes it may have a role in frontline triplets with immunotherapy. Given its favorable tolerability shown thus far, he believes it could be used in regimens like ipilimumab/nivolumab. Rini agrees triplets remain an active area of kidney cancer research.
While early efficacy signals for zanzalintinib are encouraging, both experts reiterate that substantially more data is still required to determine where it fits among existing therapies. But it may address an unmet need for a tolerable TKI backbone for immunotherapy combinations.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.